Niemann-Pick Disease, type C1 (NPC1) is a neurodegenerative disorder due to a defect in intracellular lipid and cholesterol transport. As part of a Bench-to-Bedside initiative, we initiated a clinical protocol focused on identifying and characterizing biomarkers that could be used in a subsequent therapeutic trial. Funding to support a research nurse was provided by both the Ara Parseghian Medical Research Foundation and Danas Angels Research Trust. This protocol was initiated in August 2006, and to date we have enrolled seventyfive NPC patients. This is the largest cohorts of actively followed patients in this country. While most of the patients are children, the patients range in age from infants to adults. This protocol involves neurological, hearing, ophthalmological, psychiatric and medical evaluations. Blood, urine, and cerebral spinal fluid are being collected for biomarker analysis. Evaluations include magnetic resonance imaging combined with spectroscopy and auditory brainstem responses. We plan to continue to enroll new patients and follow this group over time. This initial observational study was instrumental in laying the foundation for a therapeutic trial of N-acetyl cystein that was initiated in September 2009. This trial was a placebo-controlled, cross-over trial that enrolled 35 NPC patients. This trial was completed in August 2010. In early 2013 we initiate a phase I trial of hydroxypropyl-beta-cyclodextran administered directly to the central nervous system in collaboration with the Therapuetics and Rare Disease Section of NCATS and multiple extramural investigators. Work is ongoing in aniticpation of organizing a multicenter clinical efficacy trial.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Ottinger, Elizabeth A; Kao, Mark L; Carrillo-Carrasco, Nuria et al. (2014) Collaborative development of 2-hydroxypropyl-*-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem 14:330-9
Hung, Ya Hui; Faux, Noel G; Killilea, David W et al. (2014) Altered transition metal homeostasis in Niemann-Pick disease, type C1. Metallomics 6:542-53
King, Kelly A; Gordon-Salant, Sandra; Yanjanin, Nicole et al. (2014) Auditory phenotype of Niemann-Pick disease, type C1. Ear Hear 35:110-7
te Vruchte, Danielle; Speak, Anneliese O; Wallom, Kerri L et al. (2014) Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest 124:1320-8
Tortelli, Brett; Fujiwara, Hideji; Bagel, Jessica H et al. (2014) Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1). Hum Mol Genet 23:6022-33
Jiang, Hui; Sidhu, Rohini; Fujiwara, Hideji et al. (2014) Development and validation of sensitive LC-MS/MS assays for quantification of HP-?-CD in human plasma and CSF. J Lipid Res 55:1537-1548
Cologna, Stephanie M; Cluzeau, Celine V M; Yanjanin, Nicole M et al. (2014) Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1. J Inherit Metab Dis 37:83-92
King, Kelly A; Gordon-Salant, Sandra; Pawlowski, Karen S et al. (2014) Hearing loss is an early consequence of Npc1 gene deletion in the mouse model of Niemann-Pick disease, type C. J Assoc Res Otolaryngol 15:529-41
Speak, Anneliese O; Te Vruchte, Danielle; Davis, Lianne C et al. (2014) Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1. Blood 123:51-60
Fan, Martin; Sidhu, Rohini; Fujiwara, Hideji et al. (2013) Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J Lipid Res 54:2800-14

Showing the most recent 10 out of 13 publications